Today: 21 May 2026
Ondas (ONDS) stock slips in premarket as $1 billion financing and new targets loom
20 January 2026
2 mins read

Ondas (ONDS) stock slips in premarket as $1 billion financing and new targets loom

New York, Jan 20, 2026, 05:32 EST — Premarket action underway.

  • Ondas shares slid roughly 5% in premarket, following a steep fall on Friday.
  • The company raised its 2026 revenue target and released preliminary 2025 numbers ahead of its March report.
  • Traders are factoring in dilution risk following a $1 billion stock-and-warrant sale.

Ondas Inc shares fell roughly 4.7% to $11.59 in Tuesday premarket, following a 5.15% drop to $12.16 last Friday. Trading volume on Friday was notably high, around 168 million shares, with prices swinging between $12.12 and $14.25.

The timing is crucial. After the long weekend, U.S. investors returned to Ondas, which saw a surge in volume following a series of corporate updates that shifted expectations and sparked new concerns over dilution.

Meanwhile, the company has shifted to simplify its narrative. Ondas now focuses on autonomous systems—drones and counter-drone tech—as well as its private wireless operations. Traders have responded by treating the stock more like a momentum play than a stable earnings story.

Ondas raised its 2026 revenue forecast to $170 million-$180 million on Friday, also sharing preliminary 2025 estimates ahead of its investor day. The company projects Q4 revenue between $27.0 million and $29.0 million, with full-year 2025 revenue hitting $47.6 million-$49.6 million. Its backlog — orders not yet recognized as revenue — stood at $65.3 million as of Dec. 31, 2025. Ondas highlighted a pro-forma cash balance of more than $1.5 billion following a recent capital raise. The preliminary figures remain unaudited, with full results expected in March 2026.

Ondas raised cash through a registered direct offering, selling 19 million shares plus pre-funded warrants for up to 41.79 million shares. Each pre-funded warrant came bundled with warrants to buy two additional shares. The total package included warrants for 121.58 million shares, all priced at a $28 exercise price. Ondas expects net proceeds around $959.2 million. If all warrants are exercised, the company could pull in about $3.4 billion more, though it warned there’s no guarantee that will happen.

A separate SEC filing revealed the company officially changed its name from Ondas Holdings Inc. to Ondas Inc. on Jan. 16. It also updated its bylaws and stock incentive documents to align with the new name.

Chief Executive Officer Eric Brock linked the rebrand to changes in scale and customer base. “Today, we operate as a scaled, global defense and security technology platform,” Brock said when unveiling the planned name change and the move of headquarters to West Palm Beach, Florida. Ondas Inc.

U.S. markets took Monday off for Martin Luther King Jr. Day, shifting the week’s first full trading session to Tuesday.

Extended-hours trading often amplifies sentiment, and Ondas has experienced large intraday swings during normal sessions too. Investors will be watching to see if buyers step in after the open and whether volume holds up or drops off once the initial orders are filled.

The downside scenario is clear-cut: preliminary figures aren’t audited, backlog might delay, and the large warrant package means dilution remains a risk if the stock climbs — or it could weigh on the shares if it stalls. Any hiccup turning orders into revenue could sting more, given how fast expectations have risen.

After Tuesday’s open, the next major trigger will be the company’s March report covering the quarter and year ending Dec. 31, 2025. That’s when investors can expect audited figures and more clarity on Ondas’s strategy for the cash it recently raised.

Stock Market Today

  • Q1 Earnings Analysis: Pegasystems Lags, Appian Leads Automation Software Stocks
    May 20, 2026, 8:03 PM EDT. As Q1 earnings wrap up in the automation software sector, Pegasystems (NASDAQ:PEGA) posted a disappointing 9.6% revenue decline to $430 million, missing analyst estimates by 7.3%. Its stock dropped 11.8% post-report. Conversely, Appian (NASDAQ:APPN) showed robust growth with a 21.5% revenue increase to $202.2 million, beating expectations by 5.6%, yet its shares fell 9.2%. The sector overall saw revenues exceed consensus by 0.8%, but stocks fell 6.5% on average after earnings. Pegasystems' approach centers on AI-driven workflow automation, while Appian offers a low-code platform for complex processes. These contrasting performances highlight varied market reactions despite solid fundamental advances in automation software driven by AI and machine learning integration.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
UPL share price slips as Advanta IPO papers hit SEBI: what the filing reveals
Previous Story

UPL share price slips as Advanta IPO papers hit SEBI: what the filing reveals

Nvidia stock price slips as China H200 talks drag; NVDA earnings date looms
Next Story

Nvidia stock price slips as China H200 talks drag; NVDA earnings date looms

Go toTop